Overcoming dose limitations using the orbital® multi-breath dry powder inhaler

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 27, Issue 2, 2014, Pages 138-147

  Young, Paul M ^a   Crapper, John ^b   Philips, Gary ^b   Sharma, Ketan ^a   Chan, Hak Kim ^c   Traini, Daniela ^a,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Pharmaxis Ltd   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d WOOLCOCK INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Antibiotics; DPI; Dry powder inhaler; High dose; Mannitol; Orbital

Indexed keywords

CIPROFLOXACIN; MANNITOL; PEARLITOL 160C; UNCLASSIFIED DRUG; AEROSOL; ANTIINFECTIVE AGENT; DRUG COMBINATION; EXPECTORANT AGENT; POWDER;

AEROSOL; ARTICLE; DRUG DELIVERY DEVICE; DRUG FORMULATION; DRUG INDICATION; DRUG STABILITY; DRY POWDER; DRY POWDER INHALER; LASER DIFFRACTION; MORPHOLOGY; PHYSICAL CHEMISTRY; RESPIRATORY TRACT INFECTION; SPRAY DRYING; CHEMISTRY; COMPARATIVE STUDY; DEVICES; DIFFERENTIAL SCANNING CALORIMETRY; DRUG COMBINATION; DRUG DELIVERY SYSTEM; EQUIPMENT DESIGN; HUMAN; MEDICINAL CHEMISTRY; MICROBIOLOGY; PARTICLE SIZE; POWDER; POWDER DIFFRACTION; RESPIRATORY TRACT INFECTIONS; SCANNING ELECTRON MICROSCOPY; X RAY CRYSTALLOGRAPHY;

AEROSOLS; ANTI-BACTERIAL AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CIPROFLOXACIN; CRYSTALLOGRAPHY, X-RAY; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; EQUIPMENT DESIGN; EXPECTORANTS; HUMANS; MANNITOL; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; POWDER DIFFRACTION; POWDERS; RESPIRATORY TRACT INFECTIONS;

EID: 84897092830     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2013.1080     Document Type: Article

References (33)

1. Niven RW: Delivery of biotherapeutics by inhalation aerosol. Crit Rev Ther Drug Carrier Syst. 199512:151-231.
2. Siekmeier R, and Scheuch G: Systemic treatment by inhalation of macromolecules - principles, problems, and examples. J Physiol Pharmacol. 200859:53-79.
3. Traini D, and Young PM: Delivery of antibiotics to the respiratory tract: an update. Expert Opin Drug Deliv. 20096: 897-905.
4. Young PM, Thompson J, Woodcock D, Aydin M, and Price R: The development of a novel high-dose pressurized aerosol dry-powder device (PADD) for the delivery of pumactant for inhalation therapy. J Aerosol Med. 200417: 123-128.
5. Babu KS, Woodcock DA, Smith SE, Staniforth JN, Holgate ST, and Conway JH: Inhaled synthetic surfactant abolishes the early allergen-induced response in asthma. Eur Respir J. 200321:1046-1049.
6. Daviskas E, Anderson SD, Brannan JD, Chan HK, Eberl S, and Bautovich G: Inhalation of dry-powder mannitol increases mucociliary clearance. Eur Respir J. 199710:2449-2454.
7. Wong W, Crapper J, Chan HK, Traini D, and Young PM: Pharmacopeial methodologies for determining aerodynamic mass distributions of ultra-high dose inhaler medicines. J Pharm Biomed Anal. 201051:853-857.
8. Geller DE, Weers J, and Heuerding S: Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere technology. J Aerosol Med Pulm Drug Deliv. 201124:175-182.
9. Bilton D, Robinson P, Cooper P, Gallagher CG, Kolbe J, Fox H, Jaques A, and Charlton B: Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J. 201138:1071-1080.
10. Everard ML: Inhaler devices in infants and children: challenges and solutions. J Aerosol Med. 200417:186-195.
11. Moore AC, and Stone S: Meeting the needs of patients with COPD: patients' preference for the Diskus inhaler compared with the Handihaler. Int J Clin Pract. 200458:444-450.
12. de Boer AH, Hagedoorn P, Woolhouse R, and Wynn E: Computational fluid dynamics (CFD) assisted performance evaluation of the Twincer disposable high-dose dry powder inhaler. J Pharm Pharmacol. 201264:1316-1325.
13. World Health Organization: The top 10 causes of death. 2011. Available at: http://who.int/mediacentre/factsheets/ fs310/en/. Accessed June 17, 2013, 2013.
14. Doring G, Flume P, Heijerman H, and Elborn JS: Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cystic Fibros. 201211:461-479.
15. Newhouse MT, Hirst PH, Duddu SP, Walter YH, Tarara TE, Clark AR, and Weers JG: Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest. 2003124:360-366.
16. Geller DE, Konstan MW, Smith J, Noonberg SB, and Conrad C: Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol. 200742:307-313.
17. Westerman EM, de Boer AH, Le Brun PP, Touw DJ, Frijlink HW, and Heijerman HG: Dry powder inhalation of colistin sulphomethate in healthy volunteers: a pilot study. Int J Pharm. 2007335:41-45.
18. Westerman EM, De Boer AH, Le Brun PPH, Touw DJ, Roldaan AC, Frijlink HW, and Heijerman HGM: Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study. J Cystic Fibros. 20076:284-292.
19. Westerman EM, Heijerman HG, and Frijlink HW: Dry powder inhalation versus wet nebulisation delivery of antibiotics in cystic fibrosis patients. Expert Opin Drug Deliv. 20074:91-94.
20. Stass H, Nagelschmitz J, Willmann S, Delesen H, Gupta A, and Baumann S: Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study. Clin Drug Investig. 201333:419-427.
21. Wilson R, Welte T, Polverino E, De Soyza A, Greville H, O'Donnell A, Alder J, Reimnitz P, and Hampel B: Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J. 201341:1107-1115.
22. US Food and Drug Administration: Guidance for Industry - Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products: Chemistry, Manufacturing and Controls Documentation. 1998.
23. Byron P, Cummings H, Nichols S, Poochikian G, Smurthwaite M, Stein S, and Truman K: Selection and validation of cascade impactor test method. In: RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr, (eds). Respiratory Drug Delivery IX, Volume I. Davis Healthcare International, River Grove, IL pp. 169-178, 2004.
24. Adi H, Young PM, Chan H-K, Agus H, and Traini D: Cospray- dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. Eur J Pharm Sci. 201040:239-247.
25. Maas SG, Schaldach G, Littringer EM, Mescher A, Griesser UJ, Braun DE, Walzel PE, and Urbanetz NA: The impact of spray drying outlet temperature on the particle morphology of mannitol. Powder Technol. 2011213: 27-35.
26. Caco AI, Varanda F, de Melo MJP, Dias AMA, Dohrn R, and Marrucho IM: Solubility of antibiotics in different solvents. Part II. Non-hydrochloride forms of tetracycline and ciprofloxacin. Ind Eng Chem Res. 200847:8083-8089.
27. Armstrong N: Mannitol. In: RC Rowe, PJ Sheskey, WG Cook, and ME Fenton, (eds). Handbook of Pharmaceutical Excipients, Volume I. Pharmaceutical Press, London pp. 479-483, 2012.
28. Patton J, and Byron P: Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 20076:67-74.
29. Adi H, Young PM, Chan H-K, Stewart P, Agus H, and Traini D: Cospray dried antibiotics for dry powder lung delivery. J Pharm Sci. 200897:3356-3366.
30. Campbell Roberts SN, Williams AC, Grimsey IM, and Booth SW: Quantitative analysis of mannitol polymorphs. X-ray powder diffractometry - exploring preferred orientation effects. J Pharm Biomed Anal. 200228:1149-1159.
31. Lee YY, Wu JX, Yang M, Young PM, van den Berg F, and Rantanen J: Particle size dependence of polymorphism in spray-dried mannitol. Eur J Pharm Sci. 201144:41-48.
32. Dillen K, Vandervoort J, Van den Mooter G, and Ludwig A: Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles. Int J Pharm. 2006314: 72-82.
33. European Pharmacopoeia (Ph.EUR). Preparations for inhalation method for analysis, chapter 2.9.18. Aerodynamic assessment of five particles.